KM Research Hub
← 返回论文库
无 KM 图 入排:待复核 图源:可得 入排置信度 0.45

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

Valeria Santini, Amer M Zeidan, Koen Van Eygen, Pierre Fenaux, Ulrich Germing, Yazan F Madanat, Azra Raza, Michael R Savona, Mikkael A Sekeres, Sylvain Thépot, Marco G Raddi, Thomas Boyer, Libo Sun, Ying Wan, Tymara Berry, Qi Xia, Fei Huang, Souria Dougherty, Shyamala Navada, Faye Feller, Rami S Komrokji, Uwe Platzbecker

Leukemia 40(2) 397-409

PMID41526614
PMCIDPMC12875879
DOI10.1038/s41375-025-02831-z
发表日期2026-01-12
入排依据:The record is an exploratory analysis of a Phase III randomized trial (IMerge) in oncology with a drug intervention. It is not eligible because it does not present a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) as a formal result; instead, it presents secondary biomarker and response-duration correlations. The original primary trial result is referenced but not reported in this abstract.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图。
摘要

摘要

Existing treatments for lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) focus on symptom relief. Until recently, altering the disease course was rarely considered a therapeutic objective. The first-in-class, direct, competitive telomerase inhibitor, imetelstat, demonstrated significantly higher rates of red blood cell (RBC) transfusion independence (TI) versus placebo in patients with non-del(5q), RBC transfusion-dependent LR-MDS who were relapsed/refractory to or ineligible for erythropoiesis-stimulating agents in the Phase 3 IMerge study (NCT02598661). In this exploratory analysis of IMerge, patients treated with imetelstat had greater sustained reductions in variant allele frequency of multiple mutations versus placebo recipients, which was positively associated with RBC-TI duration. Subsequent analyses showed that 70% of patients with a cytogenetic response with imetelstat achieved ≥1-year RBC-TI. Additionally, higher rates of ≥1-year RBC-TI were observed in patients with maximum variant allele frequency reduction of ≥50% in SF3B1 (58% vs. 7%), TET2 (90% vs. 9%), DNMT3A (100% vs. 13%), or ASXL1 (50% vs. 0%) and patients with ≥50% bone marrow ring sideroblast reduction (46% vs. 0%) versus patients who did not. Lastly, 60% of patients with ≥1-year RBC-TI had ≥50% reduction in telomerase activity/human telomerase reverse transcriptase RNA. These results suggest that imetelstat targets clonal progenitor cells and may modify LR-MDS biology.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Effects on VAF reduction in imetelstat-treated patients and placebo recipients. A Heat map for maximum percent reduction of mutational VAF in the overall patient population. a Patients rank-ordered by RBC-TI duration with the longest RBC-TI on the left and shortest RBC-TI on the right of the panel. B Mean value of absolute VAF in SF3B1 and TET2 mutations over time in the overall patient population grouped by treatment arm. b C Mean value of absolute VAF in SF3B1 and TET2 mutations over time in the imetelstat treatment arm grouped by RBC-TI response. b a The percentage change from baseline in mutational VAF was evaluated for patients with VAF value ≥10% at baseline and ≥1 posttreatment mutation assessment. b Patients who received ≥1 dose of study drug and had baseline mutation of SF3B1 or TET2 and ≥1 postbaseline assessment were included. Data points with only 1 ongoing patient remaining are not shown. RBC red blood cell, SE standard error, TI transfusion independence, VAF variant allele frequency.
非 KM Figure
Fig. 2Association between VAF reduction and RBC-TI. A Maximum percent VAF reduction from baseline in select genes by RBC-TI response in patients treated with imetelstat. a B ≥1-year RBC-TI rate comparison between patients with or without change in other disease modification indicators with imetelstat treatment. a The p values are based on type III sums of squares from analysis of variance model for equality of means. Total n ’s represent patients in the imetelstat arm who had a VAF assessment ≥10 at baseline and had ≥1 postbaseline mutation assessment. b RS-negative patients were not included in the analysis of reduction in BM RS. BM bone marrow, CR complete response, IRC independent review committee, PR partial response, RBC red blood cell, RS ring sideroblast, TI transfusion independence, VAF variant allele frequency. ○ Represents an outlier observation.
非 KM Figure
Fig. 3Heatmap for mutational VAF percent change over time in patients with ≥1-year RBC-TI with imetelstat. a a Emerging mutations were not included (see Table 2 ). RBC red blood cell, TI transfusion independence, VAF variant allele frequency.
非 KM Figure
Fig. 4Transfusion history and RBC-TI intervals for patients who achieved ≥1-year RBC-TI with imetelstat treatment. RBC red blood cell, TI transfusion independence.
非 KM Figure
Fig. 5Correlation between reductions in SF3B1 VAF, BM RS cells, and central Hb increase in the cohort of patients treated with imetelstat. A Correlation between maximum change in Hb from baseline and maximum percentage reduction from baseline in BM RS in patients treated with imetelstat. a B Correlation between maximum percentage reduction from baseline in BM RS and maximum percentage reduction from baseline in SF3B1 VAF in patients treated with imetelstat. b C Correlation between maximum VAF percentage reduction in SF3B1 versus maximum Hb change from baseline in the population with both VAF and central Hb data available ( N = 68). D Mean VAF percentage reduction from baseline in SF3B1 , mean change in central Hb levels from the minimum Hb level in patients who achieved ≥1-year RBC-TI, and mean percentage change from baseline in BM RS cells in RS-positive patients with MDS who achieved ≥1-year RBC-TI. a The fitted line and p value are based on linear regression with maximum change in central Hb from pretreatment Hb as dependent variable and the maximum percentage reduction from baseline in central BM RS as independent variable. N represents imetelstat-treated patients who were RS positive and had baseline RS ≥15% with ≥1 postbaseline assessment. b The fitted line and p value are based on linear regression with maximum reduction in central BM RS as dependent variable and the maximum percentage reduction from baseline in SF3B1 VAF as independent variable. N represents imetelstat-treated patients who were RS positive, had baseline assessment ≥10% in SF3B1 and had baseline RS ≥15% with ≥1 postbaseline assessment. BM bone marrow, Hb hemoglobin, RBC red blood cell, RS ring sideroblast, TI transfusion independence, VAF variant allele frequency.
非 KM Figure